Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes ozanimod No direct evidence (very low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
RR 1.19 [0.74, 1.91]
Studies not reported
Very low

Intervention not reported

Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention showed no clear difference in ozanimod No direct evidence (low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
OR 1.01 [0.52, 1.95]
Studies not reported
Low

Intervention not reported

Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ozanimod No direct evidence (very low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
OR 1.5 [0.85, 2.64]
Studies not reported
Very low